Open Access

Human Neuroepithelial Cells Express NMDA Receptors

  • Christopher D Sharp1,
  • M Fowler3,
  • TH JacksonIV1,
  • J Houghton1,
  • A Warren1,
  • A Nanda2,
  • I Chandler1,
  • B Cappell1,
  • A Long1,
  • A Minagar4 and
  • JS Alexander1Email author
BMC Neuroscience20034:28

https://doi.org/10.1186/1471-2202-4-28

Received: 14 March 2003

Accepted: 13 November 2003

Published: 13 November 2003

Abstract

L-glutamate, an excitatory neurotransmitter, binds to both ionotropic and metabotropic glutamate receptors. In certain parts of the brain the BBB contains two normally impermeable barriers: 1) cerebral endothelial barrier and 2) cerebral epithelial barrier. Human cerebral endothelial cells express NMDA receptors; however, to date, human cerebral epithelial cells (neuroepithelial cells) have not been shown to express NMDA receptor message or protein. In this study, human hypothalamic sections were examined for NMDA receptors (NMDAR) expression via immunohistochemistry and murine neuroepithelial cell line (V1) were examined for NMDAR via RT-PCR and Western analysis. We found that human cerebral epithelium express protein and cultured mouse neuroepithelial cells express both mRNA and protein for the NMDA receptor. These findings may have important consequences for neuroepithelial responses during excitotoxicity and in disease.

Keywords

Glutamate NMDA Neuroepithelial Human Brain

Background

Glutamate receptor stimulation is an important physiological event, which helps regulate learning and memory development. [1]. In the mammalian nervous system, L-glutamate binds to several classes of 'glutamatergic' receptors, which are classified into two major groups, metabotropic and ionotropic. Within the ionotropic family of glutamate receptors there are three subtypes (based upon their binding and activation by AMPA, kainic acid, and NMDA): 1) α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), 2) kainic acid (KA) receptors, and 3) N-methyl-D-aspartate (NMDA) receptors [2].

Glutamate is present at concentrations ranging from 18–25 μM in plasma [3], 0.3 μM in the cerebral spinal fluid (CSF), and as high as 3 mM within the parenchymal cell stores [46]. However, under ischemic or traumatic conditions the glutamate concentration levels in the brain interstitial space can increase 55-fold [7] to levels that are toxic to neurons.

During stroke and trauma it has been suggested that majority of glutamate released (although not the only pathway) is due to neuronal injury within the cerebrum, which is provoked by cerebral oxygen and glucose deprivation, resulting in the excessive release of stored synaptic glutamate. Glutamate synaptic release is due to the loss of ATP stores and dissipation of membrane ion gradients leads to K+ efflux, and membrane depolarization. Eventually anoxia triggers a massive depolarization and opening of voltage-dependent Na+ channels. As a result, glutamate is released by synaptic exocytosis and trapped in the interstitium, due to the reversal of the glutamate transporters flooding the synaptic space with glutamate. This response in turn leads to the massive over-stimulation of NMDA receptors, referred to as 'glutamate excitotoxicity' [811]. In addition to neuronal excitotoxicity, increased extracellular glutamate may also contribute to 'vasogenic edema' (characterized by an increase in microvascular solute permeability) [1218].

In the hypothalamus, neuroepithelial or ependymal cells create a second brain solute "barrier" [19], which separates the brain parenchyma from the CSF. If the neuroepithelium maintains the same tight junctional characteristics as non-cerebral epithelial cells, then they will create a significantly tighter barrier than those formed by most of the endothelium, including that of the blood brain barrier (BBB) [2022]. During inflammation extracellular pathogens may penetrate the cerebrum through both the endothelial and epithelial barriers, demonstrating that infection of the cerebrum can occur from the direction of either the blood or the CSF [23]. These data suggest that the CSF barrier, like that of the endothelium, might also be compromised in disease.

In this study we demonstrated NMDA receptor expression on cerebral epithelia within human cerebral tissue and murine neuroepithelial cells. The presence of the NMDA receptor 1 (NMDAR1) on human neuroepithelium is demonstrated via immunohistochemistry and mRNA and protein expression for the NMDA receptors in cultured murine neuroepithelial cells suggest that their function is conserved among species.

Results

V1 (neuroepithelial cells) and Normal Human Brain Tissue RT-PCR for NMDAR1

Human cerebral endothelial cells (IHEC), which had previously been shown to express mRNA for NMDAR1 [24], were used as a positive control for determining if the V1 cells contained message for the NMDAR1. With the use of primer sets designed for NMDAR1 we were able to demonstrate that the V1 cells contained message for NMDAR1 (Figure 1). Figure 1 shows a ~680 bp band that was specifically amplified.
Figure 1

RT-PCR (30 cycles) was performed with primers specific for mouse and human NMDAR1, which revealed that both V1 (mouse neuroepithelial cells) and IHEC (Human cerebral endothelial cells – positive control) express mRNA for NMDAR1. The bands were determined to be ~680 bps and ~670 bps and match the anticipated size of mouse and human NMDAR1 (respectively).

V1 and Normal Rat Cerebral Tissue Western Analysis for NMDAR 1 and 2A/B

Rat cerebral lysate (positive control supplied by Chemicon) and Neuroepithelial cell protein from V1 cells were separated on SDS-PAGE gels and western blots (using antibodies specific for NMDAR1 and NMDAR2A/B) showed a ~116 and ~160 KD bands, the anticipated sizes for NMDA receptor subunit 1 and 2A/B, respectively (Figure 2). This matches the two reported size bands by Sharp et al. 2002 [24].
Figure 2

V1 cell protein and rat brain lysate positive control (supplied by Chemicon) were separated on 7.5% denaturing SDS-PAGE gels. Comparison of the control and V1 cell band (~116 kD) present after western analysis demonstrated that V1 cells do express protein for NMDA subunits 1 and 2A/B.

Human Hypothalamic Immunohistochemistry for the NMDAR1

Immunohistochemical staining of a human adult hypothalamic paraffin slide revealed that the cerebral epithelial cells (Choroid Plexus epithelial cells, Figure 3A, and ependymal cells, Figure 3B) express NMDAR1, which appeared to be concentrated on the apical (ventricular/CSF) side. We found that staining appeared to be segregated to the apical side (CSF compartment) of the nucleus. Other sections were used to examine control staining and confirmed the specificity of the antibody and procedure.
Figure 3

Human hypothalamus sections (A = choriod plexus and B = ependymal cell barrier) were stained for NMDAR1 and demonstrated a uniform and consistent pattern of staining that is associated with the apical side (CSF) with very little staining basally. The magnified section of Figure 3, further illustrates this specific orientation (also pointed out by the arrows). The blood vessels are labeled 'BV' and nuclei are labeled "N".

Discussion

Extracellular pathogens can penetrate the cerebrum through either the epithelial and endothelial barrier during events such as stroke and cerebral inflammation [23]. Many studies have considered possible mechanisms for the endothelial barrier disruption during trauma/excitotoxicity. We have recently reported that when the human cerebral endothelium was stimulated with either glutamate or NMDA there was a NMDA-type glutamate receptor dependent cerebral endothelial barrier dysfunction [24]); however, the mechanisms through which the neuroepithelial barrier might be disrupted have not been investigated. If neuroepithelial cells express NMDAR1, then during excitotoxic events (like stroke), when the CSF glutamate concentration increases, there could be a massive efflux of Ca2+ into the neuroepithelial cells. Altered intracellular Ca2+ might then lead to an increase in solute permeability, as has been proposed within endothelial systems [25].

Neuroepithelial cells also express highly efficient glutamate transporters, which are at least partially responsible for maintaining the low concentrations of glutamate in the CSF by actively moving glutamate from the CSF to the parenchyma [26, 27]. In fact these transporters create a 7-fold higher concentration of glutamate in the parenchyma (compared to the CSF) in under 5 min (with steady state reached within 15 min, as high as 30-fold) [26]. These cells also metabolize glutamine to glutamate in addition to transporting glutamate across the epithelia [26, 27]. Therefore, NMDA receptors present on the "apical" surface might regulate the activity of these transporters to control glutamate homeostasis between CSF and parenchyma.

Immunohistochemical staining of the human ependymal sections demonstrated that the nuclei separated the neuroepithelial cells into apical (facing the CSF) and basolateral (facing the parenchyma/vascular) surfaces. We saw a clear and distinct spatial association of NMDAR1 staining with the apical side with a paucity of basal staining, suggesting that the neuroepithelial cells could possibly function as detectors of CSF glutamate concentration levels, which are normally 0.3 μM but have been shown to increase 55-fold under ischemic/traumatic conditions [7]. These data support possible roles for NMDA-receptors in regulating glutamate transporters, as previously described.

Conclusion

Therefore, the results of the present study, which evaluated neuroepithelial cell expression of NMDA-type glutamate receptors via RT-PCR, Western analysis, and immunohistochemistry supports the position that cerebral epithelia express the NMDA-receptor at the mRNA (Figure 1), protein (Figure 2), and tissue levels (Figure 3). As stated above, two potential roles for neuroepithelial NMDA receptors may include: 1) control of CSF homeostasis by controlling the activity of the glutamate transporters and 2) disruption of the neuroepithelial barrier during disease/excitotoxic processes; however, we can only currently speculate on the function of these receptors. Future studies will examine each of these possible functions of the neuroepithelial NMDA receptor.

Methods

Reagents for Tissue Culture

M-199, Insulin, Transferrin, Selenium, Heparin, and HEPES were purchased from Sigma (St. Louis, MO).

Cell culture

A mouse neuroepithelial cell line (termed "V1") was supplied by Dr. Harvey Ozer (University of Medicine and Dentistry of New Jersey, Newark). V1 cells were maintained in M-199 (with 10% FCS, 1% antibiotic/antimycotic, 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml Selenium, and 600 USP units/l heparin) and grown to 100% confluency on T-75 flask. The neuroepithelial cultures were used at 1 week in culture (approximately 3 days after culture confluency was established).

Western Analysis

Protein samples (25 ug each) were separated on 7.5% SDS-PAGE gels, electro-transferred to nitrocellulose membranes and blocked overnight in 5% milk in PBS. Membranes were then incubated for 24 hours with anti-human NMDAR1 and an anti-human NMDAR2A/B (Chemicon; Temecula, CA) polyclonal antibody at 1:250 dilution in 0.1% milk in PBS. The membranes were then washed 3 × 5' (each wash) and incubated overnight at 4°C in goat anti-mouse alkaline-phosphatase secondary antibody (Sigma; St. Louis, MO) at a 1:1000 dilution in 0.1% milk in PBS. The membranes were then reacted with NBT/BCIP chromogen to visualize the proteins.

RT-PCR

Message for NMDAR1 was determined in both V1 cells and human brain tissue samples from total RNA (Qiagen kit number 52304; Qiagen; Seattle, WA). 1 ug of DNAse treated RNA was converted to cDNA using reverse transcriptase (Promega; Madison, WI) and amplified using the following primers (from ascension number BC039157; sense primer for base pairs 1192–1209 and antisense primer for base pairs 1854-1838): sense primer, 5'-GATGTCTTCCAAGTATGC-3' and antisense primer, 5'-ATCTCCTTCTTGACCAG-3'. The PCR mixture was amplified for 30 cycles using a three step protocol: denaturation at 94°C (1 min), annealing at 50°C for 1 min, and elongation at 72°C for 1 min. The corresponding 670 – 680 bp (NMDAR1) product was separated in a 1.5% agarose gel stained with ethidium bromide and viewed and analyzed using Alpha Innotech gel documentation system (San Leandro, CA). RNA extracts from human cerebral endothelial cells (IHEC) were used as the positive control for all experiments [24]. Negative controls were performed in which the reverse transcriptase enzyme was omitted and replaced with RNAse free water.

Immunohistochemistry

Paraffin slides were deparaffinized with 2 changes of xylene (Sigma; St. Louis, MO) for 10 min each. The slides were transferred to 100% alcohol for 2 changes for 2 min each. They were incubated for 10 min in 3% H2O2 in methanol to block endogenous peroxidase activity. The slides were rinsed 1× in PBS and excess PBS removed. Slides were blocked with 5% normal serum for 1 hour and then the anti-human NMDAR1 (Chemicon; Temecula, CA) polyclonal antibody at a 1:250 dilution in 0.1% milk (in PBS) was added and allowed to incubate at 4°C overnight. The next day the slides were rinsed 3× for 2 min each in PBS. HRP (Sigma; St. Louis, MO) at a 1:1000 dilutions in 0.1% milk was applied to the slides and incubated for 30 min at room temperature. The slides were washed 3 times in PBS and diaminobenzidine (DAB) solution (Pharmingen; San Diego, CA) was applied and allowed to incubate for 5 min. The DAB was drained and the slides were placed in water for 3 min. Slides were counter-stained in hematoxylin (Pharmigen; San Diego, CA). The slides were then dehydrated with the use of 100% alcohol and then mounting medium and coverslips were applied.

Declarations

Authors’ Affiliations

(1)
Department of Molecular and Cellular Physiology, LSU Health Sciences Center
(2)
Department of Neurosurgery, LSU Health Sciences Center
(3)
Department of Pathology, LSU Health Sciences Center
(4)
Department of Neurology, LSU Health Sciences Center

References

  1. Nicoll RA, Oliet SHR, Malenka RC: NMDA Receptor-Dependent and Metabotropic Glutamate Receptor-Dependent Forms of Long-Term Depression Coexist in CA1 Hippocampal Pyramidal Cells. Neurobiol Learn Mem. 1998, 70: 62-72. 10.1006/nlme.1998.3838.PubMedView ArticleGoogle Scholar
  2. Hollmann M, O'Shea-Greenfield A, Rogers SW, Heinemann S: Cloning by functional expression of a member of the glutamate receptor family. Nature. 1989, 342: 643-648. 10.1038/342643a0.PubMedView ArticleGoogle Scholar
  3. Bos KD, Slump P: Determination of glutamine and glutamate in plasma of men and women by ion exchange chromatography. Clin Chim Acta. 1985, 152: 205-211. 10.1016/0009-8981(85)90193-7.PubMedView ArticleGoogle Scholar
  4. Fonnum F: Glutamate: a neurotransmitter in mammalian brain. J Neurochem. 1984, 42: 1-11.PubMedView ArticleGoogle Scholar
  5. Coyle JT, Bird SJ, Evans RH, Gulley RL, Nadler JV, Nicklas WJ, et al: Excitatory amino acid neurotoxins: selectivity, specificity, and mechanisms of action. Based on an NRP one-day conference held June 30, 1980. Neurosci Res Program Bull. 1981, 19: 1-427.PubMedGoogle Scholar
  6. Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993, 262: 689-695.PubMedView ArticleGoogle Scholar
  7. Bogaert L, Scheller D, Moonen J, Sarre S, Smolders I, Ebinger G, et al: Neurochemical changes and laser Doppler flowmetry in the endothelin-1 rat model for focal cerebral ischemia. Brain Res. 2000, 887: 266-275. 10.1016/S0006-8993(00)02959-0.PubMedView ArticleGoogle Scholar
  8. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994, 330: 613-622. 10.1056/NEJM199403033300907.PubMedView ArticleGoogle Scholar
  9. Olney JW: Glutamate, a neurotoxic transmitter. J Child Neurol. 1989, 4: 218-226.PubMedView ArticleGoogle Scholar
  10. Kempski O, von Andrian U, Schurer L, Baethmann A: Intravenous glutamate enhances edema formation after a freezing lesion. Adv Neurol. 1990, 52: 219-223.PubMedGoogle Scholar
  11. Kempski O: Cerebral edema. Semin Nephrol. 2001, 21: 303-307. 10.1053/snep.2001.21665.PubMedView ArticleGoogle Scholar
  12. Rosenberg GA: Ischemic brain edema. Prog Cardiovasc Dis. 1999, 42: 209-216.PubMedView ArticleGoogle Scholar
  13. Abbott NJ: Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000, 20: 131-147. 10.1023/A:1007074420772.PubMedView ArticleGoogle Scholar
  14. Gorgulu A, Kins T, Cobanoglu S, Unal F, Izgi NI, Yanik B, et al: Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir (Wien). 2000, 142: 1287-1292. 10.1007/s007010070027.View ArticleGoogle Scholar
  15. Reynolds IJ, Hastings TG: Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci. 1995, 15: 3318-3327.PubMedGoogle Scholar
  16. Brahma B, Forman RE, Stewart EE, Nicholson C, Rice ME: Ascorbate inhibits edema in brain slices. J Neurochem. 2000, 74: 1263-1270.PubMedView ArticleGoogle Scholar
  17. Buckman JF, Reynolds IJ: Spontaneous changes in mitochondrial membrane potential in cultured neurons. J Neurosci. 2001, 21: 5054-5065.PubMedGoogle Scholar
  18. Urushitani M, Nakamizo T, Inoue R, Sawada H, Kihara T, Honda K, et al: N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res. 2001, 63: 377-387. 10.1002/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#.PubMedView ArticleGoogle Scholar
  19. Marone M, Quinones-Jenab V, Meiners S, Nowakowski RS, Ho SY, Geller HM: An immortalized mouse neuroepithelial cell line with neuronal and glial phenotypes. Dev Neurosci. 1995, 17: 311-323.PubMedView ArticleGoogle Scholar
  20. Alexander JS, Blaschuk OW, Haselton FR: An N-cadherin-like protein contributes to solute barrier maintenance in cultured endothelium. J Cell Physiol. 156 (3): 610-618.Google Scholar
  21. Ban Y, Wilt SD, Rizzolo LJ: Two secreted retinal factors regulate different stages of development of the outer blood-retinal barrier. Brain Res Dev Brain Res. 119 (2): 259-267.Google Scholar
  22. Wegener J, Sieber M, Galla HJ: Impedance analysis of epithelial and endothelial cell monolayers cultured on gold surfaces. J Biochem Biophys Methods. 1996, 32 (3): 151-70. 10.1016/0165-022X(96)00005-X.PubMedView ArticleGoogle Scholar
  23. Nassif X, Bourdoulous S, Eugene E, Couraud PO: How do extracellular pathogens cross the blood-brain barrier?. Trends Microbiol. 2002, 10: 227-232. 10.1016/S0966-842X(02)02349-1.PubMedView ArticleGoogle Scholar
  24. Sharp CD, Hines IN, Warren AC, Elrod JW, Jennings M, Laroux FS, et al: NMDA receptor (NMDAR1) dependent oxygen radicals disrupt junctional barrier in human brain endothelial monolayers. FASEB J. 2002, 16 (5): A1124.Google Scholar
  25. Rotrosen D, Gallin JI: Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin, and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol. 1986, 103: 2379-2387.PubMedView ArticleGoogle Scholar
  26. Kim CS, Virella A, Braunberg RC, Ross IA, Matthews RN, Johnson W, et al: Kinetic analysis of glutamate transport by the miniswine choroid plexus in vitro. Brain Res. 1996, 709: 59-64. 10.1016/0006-8993(95)01263-X.PubMedView ArticleGoogle Scholar
  27. al Sarraf H, Preston JE, Segal MB: Acidic amino acid accumulation by rat choroid plexus during development. Brain Res Dev Brain Res. 1997, 102: 47-52.PubMedView ArticleGoogle Scholar

Copyright

© Sharp et al; licensee BioMed Central Ltd. 2003

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement